EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nanobody‐Decorated Lipid Nanoparticles for Enhanced mRNA Delivery to Tumors In Vivo

Pol Escudé Martinez de Castilla iD, Vincenzo Verdi iD, Willemijn de Voogt iD, Mariona Estapé Sentí, Arnold C Koekman, Julian Rietveld, Sven van Kempen, Qiangbing Yang, Juliette van Merris, Guido Jenster, Martin E van Royen, Marcel H Fens und 5 weitere

Advanced Healthcare Materials · 2025

DOI: 10.1002/adhm.202500605 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Pol Escudé Martinez de Castilla und 16 weiteren Autor:innen. Beteiligte Einrichtung: CDL Research, University Medical Center Utrecht, Utrecht, 3584CX, The Netherlands. Hauptthemen laut MEDLINE: Nanoparticles, Single-Domain Antibodies, RNA, Messenger, Prostatic Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation ARC pour la Recherche sur le Cancer, Fondation pour la Recherche Médicale, Agence Nationale de la Recherche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PCa) ranks as the fifth leading cause of cancer‐related deaths among men worldwide. In 10–20% of the cases, PCa progresses to an incurable, castration‐resistant stage. Castration‐resistant PCa cells often overexpress prostate‐specific membrane antigen (PSMA), a membrane protein that may serve as their Achilles' heel. Over the past decades, RNA‐based therapeutics have emerged as promising treatments for a vast array of diseases, including cancer. In this study, with the ultimate goal of developing a targeted therapy for PCa, lipid nanoparticles (LNPs) are decorated with an anti‐PSMA nanobody using click chemistry with a PEG‐lipid. Direct stochastic optical reconstruction microscopy (dSTORM) and cluster analysis confirm the presence of at least one nanobody on the surface of 80% of LNPs. These anti‐PSMA LNPs exhibit enhanced and specific uptake, and mRNA transfection in PSMA+ cancer cells both in vitro and in a Zebrafish (ZF) metastatic PCa xenograft model. Additionally, in a mouse PSMA‐positive xenograft model, systemic administration results in increased LNP accumulation, but not functional mRNA delivery. These findings underscore both the potential and the challenges of using a PSMA‐targeted lipid nanoparticle system for mRNA delivery into advanced prostate cancer tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesSingle-Domain AntibodiesRNA, MessengerProstatic NeoplasmsLipidsAnimalsHumansMaleZebrafishMiceCell Line, TumorGlutamate Carboxypeptidase IIAntigens, SurfaceLiposomes

Stichwörter der Autor:innen

mRNA‐lipid nanoparticlesnanobodyprostate cancerprostate specific membrane antigen (PSMA)targeted delivery

Substanzen

Single-Domain AntibodiesRNA, MessengerLipidsLipid NanoparticlesGlutamate Carboxypeptidase IIAntigens, SurfaceFOLH1 protein, humanLiposomes

Autor:innen und Institutionen

  • CDL Research, University Medical Center Utrecht, Utrecht, 3584CX, The Netherlands.
  • Institut de Psychiatrie et Neurosciences de Paris, Université Paris Cité, INSERM 1266, Paris, 75014, France.
  • Laboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD, 20892, United States.
  • Department of Pathology, University Medical Center Utrecht, Utrecht, 3584CX, The Netherlands.
  • Department of Urology, Erasmus MC, Rotterdam, 3015GD, The Netherlands.
  • Department of Pathology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, 3015GD, The Netherlands.

ORCID-Profile: Pol Escudé Martinez de Castilla, Vincenzo Verdi, Willemijn de Voogt, Raymond M Schiffelers

Förderung

  • Fondation ARC pour la Recherche sur le Cancer
  • Fondation pour la Recherche Médicale
  • Agence Nationale de la Recherche
  • Horizon 2020
  • HORIZON EUROPE Marie Sklodowska-Curie Actions

Zitieren

APA

Escudé Martinez de Castilla, P., Verdi, V., de Voogt, W., Estapé Sentí, M., Koekman, A. C., Rietveld, J., van Kempen, S., Yang, Q., van Merris, J., Jenster, G., van Royen, M. E., Fens, M. H., Kooijmans, S. A. A., van Weerden, W. M., van Niel, G., Vader, P., & Schiffelers, R. M. (2025). Nanobody‐Decorated Lipid Nanoparticles for Enhanced mRNA Delivery to Tumors In Vivo. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202500605

Vancouver

Escudé Martinez de Castilla P, Verdi V, de Voogt W, Estapé Sentí M, Koekman AC, Rietveld J, et al. Nanobody‐Decorated Lipid Nanoparticles for Enhanced mRNA Delivery to Tumors In Vivo. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202500605

BibTeX
@article{EscudMartinezdeCastilla2025,
  author = {Escudé Martinez de Castilla, Pol and Verdi, Vincenzo and de Voogt, Willemijn and Estapé Sentí, Mariona and Koekman, Arnold C and Rietveld, Julian and van Kempen, Sven and Yang, Qiangbing and van Merris, Juliette and Jenster, Guido and van Royen, Martin E and Fens, Marcel H and Kooijmans, Sander A A and van Weerden, Wytske M and van Niel, Guillaume and Vader, Pieter and Schiffelers, Raymond M},
  title = {Nanobody‐Decorated Lipid Nanoparticles for Enhanced mRNA Delivery to Tumors In Vivo},
  journal = {Advanced Healthcare Materials},
  year = {2025},
  doi = {10.1002/adhm.202500605}
}
Kostenlos starten →